Diligence memo · auto-generated · as of July 2, 2026
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
GeneCentric Therapeutics, Inc. operates in Biotechnology, based in DURHAM.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
GeneCentric Therapeutics, Inc. has raised $22M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.1M on 2016-12-22.
Most recent recorded round closed around 2025-06-04.
Valuation (modeled)modeled
Provath models GeneCentric Therapeutics, Inc. at approximately $6.7M (range $2.2M–$12M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.43× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 69% of Biotechnology peers (4293 compared).
Modeled value ranks above 13% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.